Track topics on Twitter Track topics that are important to you
AIM-listed med-tech firm ANGLE plc (LON:AGL,OTCQX:ANPCY) said its ground-breaking liquid biopsy outperformed the current tests used to tell whether a pelvic mass is malignant or benign. Its Parsortix system was able to detect cancer in 95% of the cases, achieving a lower false positive rate than existing method of detection. ANGLE’s technology was used in harness with a specially-developed algorithm using certain patient data. Results came from a study of 400 people at two centres – Vienna and New York State. Diagnosis before biopsy ANGLE believes the Parsortix blood test has the potential to aid the diagnosis of ovarian cancer before a biopsy or surgery is performed. Why does this matter? Well, it will allow those with disease to be referred directly to gynaecologic oncology surgeons. At the same time, it should ensure patients with benign tumours are be cared for in their communities. This streamlined strategy has the potential to cut costs and accelerate treatment. ANGLE’s founder and chief executive said of the latest results: “This success enables ANGLE to move forward into the validation phase for the use of Parsortix in its first clinical application. “We believe ANGLE is building momentum towards securing a leading and well differentiated commercial position in the emerging multi-billion dollar liquid biopsy market." WATCH: Our last chat with boss Andrew NewlandNEXT ARTICLE
Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...
Ovarian Cancer is cancer that starts in the female reproductive organs, the ovaries. It is the fifth most common cancer among women. Women at risk of Ovarian Cancer are those who have had few children (or had children at an older age), carriers o...